KRT18 and infection: In an in vivo efficacy study with a K18 hACE2 transgenic mouse model that was highly pathogenic after infection with SARS-CoV-2 [15], GIGA-2050 was found to significantly reduce mortality compared to the no treatment control group (Figure 3, p = 0.007).